European OTC Switch Still Muted By Regulatory Resistance
This article was originally published in The Tan Sheet
Executive Summary
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.
You may also be interested in...
Post-Market Monitoring Can Fill Innovative Switch Data Gaps – Consultants
Allowing for post-market monitoring would incentivize sponsors to consider switches and generate data that could inform a decision about potential conditions for safe use “without applying potentially burdensome – and possibly unnecessary – conditions upfront,” Pinney Associates health care consultancy says.
Centralized Switch Can Be Improved Via Practice, Practical Strategy
Over-the-counter drug makers can advance the EU centralized switch process by keeping the applications coming so that health authorities can "learn by doing," says Patrick Le Courtois, head of the human medicines development and evaluation unit at the European Medicines Agency
Switch Environment Makes U.K. A Sound Warm-up For Centralized Switch
The U.K.'s bullish Rx-to-OTC switch environment can make it an attractive place to try a switch before pursuing the EU-wide centralized procedure, which contains more potential pitfalls, experts say